Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.

Abstract: Provided herein are compositions, systems, kits, and methods for detecting rejection, or an elevated risk of rejection, of an organ or tissue graft (e.g., kidney graft) in a subject by detecting one, or a panel of, RNA markers in a urine sample from the subject. In certain embodiments, kidney graft injury is detected by measuring one or more of the RNA markers disclosed herein. In some embodiments, the one or more markers are employed to distinguish between acute graft rejection and BK virus nephropathy.

Abstract: Disclosed herein is an injection device with housing that defines a channel and a first injection guide opening. The first injection guide opening enters the channel in a manner that allows a needle to penetrate a vessel in an animal with accuracy and at the same time protect the user from the needle.

Abstract: The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, the present invention provides recombinant polynucleotides. In some embodiments, the recombinant polynucleotides comprise a cytomegalovirus (CMV) genome, or a portion thereof, and a nucleic acid sequence encoding an antigen, wherein the CMV genome or portion thereof comprises a mutation within a interleukin-10-like gene sequence. Methods for preventing and treating diseases such as infectious diseases and cancer are also provided herein.

Abstract: Systems and methods for controlling application of horizontal resistive force to a user walking on a treadmill to provide substantially constant force even if the user changes his or her relative position on the treadmill. The systems and methods can improve the user experience when force is applied while also improving user safety. The system has a cable, a motor, and a system controller. The cable can be coupled to a harness to apply a horizontal resistive force to a treadmill user, and the motor can be coupled to the cable and configured to apply a motor force to the cable. The cable can have an adjustable operative length. The system controller can have a processor communicatively coupled to the motor and configured to adjust the force applied by the motor in response to changes in cable length and a measurement of the actual force applied by the cable.

Abstract: Dual sequential defibrillation (DSD) systems and methods include the use of a timing device. The timing device can assist a user with DSD administration by providing notifications spaced apart by the inter-shock timing. The user can use these notifications to trigger the administration of defibrillation in a sequential manner. The timing device can also be coupled to two defibrillation devices and can output a signal to each of the defibrillation devices to cause the defibrillation device to administer a defibrillation. The output of the signals by the timing device can be spaced apart by the inter-shock timing. Additionally, the signals can be QRS-like in nature to cause the defibrillation devices to administer a defibrillation when in a sync mode.

Abstract: Novel rexinoid compounds are provided herein. Also provided herein are methods of using the compounds to treat disorders, such as metabolic disorders, diabetes, insulin resistance, glucose intolerance, obesity, steatosis, inflammation, and/or cancer.

Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.

Abstract: The present disclosure provides compositions and methods for treating and/preventing diseases and conditions associated with premature termination mutations. The methods disclosed herein comprise the step of administering to the subject a therapeutically effective dose of a compound described herein that induces read-through of the premature termination codon. The methods of the present disclosure may further comprise treating the subject with enzyme replacement therapy wherein the enzyme replacement therapy is selected for the disease or condition to be treated. Furthermore, the present disclosure provides method of pharmacologically suppressing premature termination codons in a subject in need of such suppression.

Abstract: Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.

Abstract: The disclosure provides a compound of the formula (II) and pharmaceutically acceptable salts thereof. The variables, e.g. n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful for treating cancer and fibrosis. The compounds may be particularly useful for treating forms of cancer in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred. The disclosure also provides pharmaceutical compositions containing a compound of this formula and method for treating patients having cancer, fibrosis, or other conditions in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred.

Abstract: Exemplary apparatus and method can be provided for obtaining data regarding a plurality of samples. For example, using at least one arrangement, it is possible to receive interferometric information that is based on radiations provided from a reference and the samples that are provided in respective chambers. Alternatively and/or in addition, based on the interferometric information, it is possible to discriminate between agents to identify a particular agent that affects a particular function within at least one of the samples.

Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.

Abstract: A method for detecting an open-phase condition of a transformer having a grounded-wye high voltage side connection including monitoring current flowing in a neutral connection on the high voltage side of the transformer in real time by voltage relaying and current relaying to identify an open phase condition signature in a signal capable of characterizing change of current magnitude. A current signal may be injected onto the neutral terminal and the zero-sequence mode of the transformer monitored to detect an open-phase condition indicated by an increase in network impedance and decrease or elimination of the injection current.

Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.

Abstract: Various examples of methods and apparatuses are provided for a hybrid composite gear. The hybrid composite gear includes a continuous fiber thermoplastic composite material co-molded onto a periphery of a neat thermoplastic or discontinuous fiber thermoplastic gear.

Abstract: Relationships between morphological changes to an eye due to intraocular pressure changes and blood perfusion changes in the retina are determined by colocalizing retinal perfusion data and optic nerve head (ONH) mechanical deformation data. Perfusion changes from intraocular pressure (IOP) changes are determined by colocalizing retinal perfusion data with ONH mechanical deformation data. Optical coherence tomography-angiography (OCT-A) can be used to generate both retinal perfusion data and mechanical deformation data for an imaged volume. A three-dimensional model (e.g., connectivity map or connectivity model) of the vasculature can be generated from the OCT-A imaging data and used to predict changes in blood perfusion in various areas of the retina due to IOP-induced mechanical deformations.

Abstract: A method and system for evaluating physiological properties of a segment of blood vessel is provided. The method includes: acquiring a first measurement and a second measurement respectively at the first point and the second point; obtaining a transfer function configured to produce an output given an input, using the first measurement and the second measurement as the input and the output respectively; and determining the physiological properties of the section of the blood vessel based on the transfer function. The transfer function can be a velocity transfer function based on the blood velocity waveforms, or can be a pressure transfer function based on the blood pressure waveforms. The method and system can be used to non-invasively diagnose PH, COPD, and PA impedance in a pulmonary artery, and to detect a stenosis in a coronary artery.

Abstract: Provided herein are compositions and methods for protein purification.